Documente Academic
Documente Profesional
Documente Cultură
Ph. Gorwood, Meeting everyday challenges: Antipsychotic therapy in the real world in European Neuropsychopharmacology, vol.16, Suppl.3, 2006
Scorurile iniiale la Calgary Depression Scale for Schizophrenia: ziprasidon 6.0 (n=107-126), olanzapin 5.7 (n=114-129)
S.Kasper, Optimisation of long-term treatment in schizophrenia: Treating the true spectrum of symptoms in European Neuropsychopharmacology, vol.16, Suppl.3, 2006
Cotientizare crescnd a importanei recunoaterii efectelor metabolice i cardiovasculare n tratamentul pacienilor cu schizofrenie
Obezitate
42% vs 27% n comparaie cu populaia general
Diabet
Prevalen de 2 ori mai mare ca n populaia general
Dislipidemie
Frecvent i adesori agravat de antipsihotice
Fumat
85% vs 23% n comparaie cu populaia general; risc de 3 ori mai mare
CATIE=Clinical Antipsychotic Trials of Intervention Effectiveness; CHD=coronaropatie; HDL=high-density lipoprotein; NHANES=National Health and Nutrition Examination Survey. Goff DC et al. Schizophr Res. 2005;80:45-53.
A doua generaie
Glucoz crescut
Hiperlipidemie
Coronaropatie
Prima generaie
EPS= simptome extrapiramidale.
Afinitatea pt. receptorul histaminic H1 prezice creterea n greutate 4 Spearman P= 0,72; P< 0,01*
3 2 1 0 CLOZ
1,2
OLA
2
QUE
11
RIS
15
ARI
29,7
ZIP
43
HAL
1800
6 5 4 3 2 1 0 -1 -2 -3
A. 10 spt., meta-analiz. Modif. dup Allison DB et al. Am J Psychiatry. 1999;156:1686-1696 B. *Date la 4-6 spt., adaptate dup Marder et al. Schizophr Res. 2003;61:123-136. C. Date la 6 spt., adaptate dup Jones et al. Poster presented at the ACNP annual meeting; December
1999; Nashville, TN.
CONFIDENIAL: INFORMAII DE FUNDAL, PENTRU COMUNICARE EXCLUSIV LA CERERE. A NU SE DUPLICA, DISTRIBUI SAU FOLOSI LA PROMOVARE
Respondeni (%)
50 40 30 20 10 0
t be a Di e al . if od /m i ze o c glu lic o A ab et .m r Sd l lte e
22
19 4 3 3 2 2 1
em c i l rg e ip
ie
20
15
Discontinuri (%)
Cretere n greut. >7% OLZ QTP RIS 30% 16% 14% 12% 7%
10
PER ZIP
5 4 3 2 1 0 -1 -2 -3 -4 -5 0
5,6 kg
10
15
20
25
30
*P< 0,002. Cazuri observate. Iniial: aripiprazol= 81,3 kg; olanzapin= 81,7 kg.
Weeks
RIS = netratai; OLZ > netratai RIS = netratai; OLZ > netratai OLZ > RIS OLZ > RIS OLZ = netratai; RIS >netratai RIS, QTP = netratai; OLZ > netratai RIS = CON; OLZ, QTP > CON OLZ > CON
Aripiprazol Olanzapin
19.81 12.02
10
1.75 2.04 0.9 -1.44
0.02
-10
n=
Spt. 8
55/64
Spt. 16
41/50
Spt. 26
41/53
Spt. 52
37/45
Durata tratamentului
LOCF= last observation carried forward.
Sfritul LOCF
60/65
Marcus R et al. Poster prezentat la: 158th Annual Meeting of the American Psychiatric Association; May 21-26, 2005; Atlanta, GA.
Modif. medie a colesterolului total, LDL, HDL i trigliceridelor cu aripiprazol i olanzapin la 52 Spt.
15 10 5 0 -5 -10 -15 -20 -25 -30
n=
Aripiprazol
Olanzapin
Colesterol
113/111
LDL
112/104
HDL
112/109
Trigliceride
111/108
*P= 0,003; P< 0,001. Numai pacienii cu probe bazale care au fost inclui n analizele datelor privind sigurana. HDL= high density lipoprotein cholesterol; LDL= low density lipoprotein cholesterol. Debutul nou exclude pacienii cu valori iniiale ridicate.
Data on file: CN138-003.
LDL
74 82 113 102
HDL
80 47 83 47
TG
93 91 161 143
Last observation carried forward. Probe de plasm bazale (pe nemncate). HDL= high-density lipoprotein cholesterol; LDL= low-density lipoprotein cholesterol; TG=trigliceride.
Adaptat dup Pigott et al. J Clin Psychiatry. 2003;64:1048-1056; Data on file: CN138-047.
Efectele aripiprazolului i olanzapinei asupra colesterolului total, LDL, HDL i trigliceridelor ntr-un studiu de 26 spt. (002)
Modif median fa de baseline (mg/dl) 20 15 10 5 0 -5 -10 -15 -20 -25
Colesterol total LDL HDL Trigliceride
Olanzapin Aripiprazol
n = 85/87
84/87
84/87
84/87
Datele (LOCF la punctul final) au fost obinute din probe de plasm bazale Valorile iniiale - Colesterol: O=185, A=184; LDL: O=110, A=108; HDL: O=44, A=44; trigliceride: O=159, A=162 HDL= high density lipoprotein cholesterol; LDL= low density lipoprotein cholesterol.
Diabet i boal CV
Newcomer. CNS Drugs 2005;19(Supp 1):1.93.
Sindrom metabolic
sunt necesari 3 factori de risc
ATP III A*
IDF**
dac se ndeplinesc 3 din 5 criterii.; **MetSynd dac se ndeplinesc 2 criterii adiionale (circumferina taliei este obligatorie); ***Sau dac face tratament cu medicaie antihipertensiv; ****Sau dac face tratament cu insulin sau medicaie hipoglicemiant.
47,6 n=64
512,9 n=299
1017,5 n=50
160 n=294
307 n=47
30 n=1294
Reducerea
simptomelor
Recuperarea,
ameliorarea calitii vieii
4 s.
8 s.
12 s.
3 l.
12 l. X
5 ani
X X X X X X X X X X X X X
X X X X
Scopurile terapeutice
Reducerea greutii BMI: <25 Circumferina taliei M: 102 cm.; F: 89 cm. Indexul glicemic HbA1c: <7% ADA; <6,5% AACE FBS: 100 mg/dL; 100-125 mg/dL OGTT: 200 mg/dL n 2 ore Hipertensiune 130/85 mm Hg Dislipidemie LDL: <100 mg/dL HDL: brbai >45 mg/dL; femei >55 mg/dL Trigliceride: <150 mg/dL Fumat ncetare
Adult Treatment Panel III. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and the Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Bethesda, MD: National Institutes of Health; 2002. NIH Publication No. 02-5215.